Relmada Therapeutics initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of Relmada Therapeutics (RLMD) with a Buy rating and $14 price target Relmada is a clinical-stage biotechnology whose core focus is on NDV-01, a sustained-release formulation of gemcitabine and docetaxel being investigated for high risk and intermediate risk non-muscle invasive bladder cancer, the analyst tells investors in a research note. The firm says the 5-minute visit time for NDV-01 is a “significant differentiator already.”